Catalio Capital Management
Catalio Capital Management reported 39 stocks worth $532M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are AVLN (10.4%), JNJ (6.6%) and GILD (6.4%). Compared with Q1 2026, the fund opened new positions in AVLN, JNJ and PBLS, added to GILD, BBIO and SNDX, trimmed DFTX, BMY and EW and sold out of ASND, BSX and CYTK.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 7 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  AVLN Avalyn Pharma Inc | $55.2M | 10.4% | 1.7M | New position | 1 of 7 | |
| 2 |  JNJ Johnson & Johnson | $35.3M | 6.6% | 139K | New position | 2 of 7 | |
| 3 |  GILD Gilead Sciences Inc | $34M | 6.4% | 269K | +105K (+64%) | 4 of 7 | |
| 4 |  BBIO Bridgebio Pharma Inc | $33.9M | 6.4% | 455K | +23K (+5%) | 6 of 7 | |
| 5 |  SNDX Syndax Pharmaceuticals Inc | $26.6M | 5.0% | 1.2M | +172K (+16%) | 6 of 7 | |
| 6 |  DFTX Definium Therapeutics Inc | $26.5M | 5.0% | 563K | −475K (−46%) | 2 of 7 | |
| 7 |  BMY Bristol Myers Squibb Co | $23.8M | 4.5% | 413K | −7,766 (−2%) | 4 of 7 | |
| 8 |  PBLS Parabilis Medicines Inc Com | $22.6M | 4.2% | 824K | New position | 1 of 7 | |
| 9 |  NTRA Natera Inc | $22.3M | 4.2% | 82K | +11K (+16%) | 5 of 7 | |
| 10 |  INCY Incyte Corp | $21.7M | 4.1% | 192K | +9,526 (+5%) | 2 of 7 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
 ASND Ascendis Pharma A/s | $29.5M | 129K |
TERNS PHARMACEUTICALS INC | $21.6M | 409K |
SOLENO THERAPEUTICS INC | $19.3M | 578K |
 BSX Boston Scientific Corp | $18.8M | 299K |
 CYTK Cytokinetics Inc | $14.2M | 216K |
🔒 Free account: see all 13.
Reported value
last 7 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Catalio Capital Management 13F FAQ
What does Catalio Capital Management own?
Catalio Capital Management reported 39 stocks worth $532M in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are AVLN (10.4%), JNJ (6.6%) and GILD (6.4%). The table above lists every position in the filing (the top 10 without an account).
What did Catalio Capital Management buy and sell in Q2 2026?
Compared with Q1 2026: 11 new positions, 15 added to, 8 trimmed and 13 sold out. New positions include AVLN, JNJ and PBLS. It sold all of ASND, BSX and CYTK.
When will Catalio Capital Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Catalio Capital Management's portfolio worth?
The Q2 2026 filing reports $532M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.